Blood Cancer UK focuses on research, support, and care for individuals affected by blood cancer, including leukaemia, lymphoma, and myeloma.

Blood Cancer UK

Childhood Eye Cancer Trust focuses on supporting individuals affected by retinoblastoma, providing resources and information about the condition.

Childhood Eye Cancer Trust

Blood Cancer UK focuses on research, support, and care in the field of blood cancer.

Blood Cancer UK | 9,488 followers on LinkedIn. We&#39;re a community dedicated to beating blood cancer- leukaemia, lymphoma, myeloma through research.

Leadership Coach and Consultant

John Reeve

Agent/Broker

Brian M. White

Health Equity Advocate | Thought Leader in Planetary Health, Research, and Patient Advocacy | Ph.D. Medical Humanities

Dr Yewande Okuleye Ph.D, FRHistS

Programme & strategy manager | Net Zero, Industrial Decarbonisation | Charity board member | Policy advisor.

Aileen Lamb

Further strides forward for our blood cancer community! Two new treatments for use on the NHS in Scotland have just been approved 🎉 🙌 The approval includes Yescarta, a CAR-T therapy for adults diagnosed with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Roughly 450 people are diagnosed in Scotland each year, and this will give opportunity to be treated with CAR-T therapy sooner. Vanflyta has been approved for the treatment of newly diagnosed (FLT3-ITD-positive) acute myeloid leukaemia (AML) on the NHS in Scotland. The drug is to be used in combination with standard cytarabine & anthracycline induction, & standard cytarabine consolidation chemo. In Scotland, around 150 people were diagnosed with AML per year, and FLT3-ITD mutations are detected in approximately 25% of cases. Despite this, until now, there were no treatments in Scotland which targeted the ITD mutation. These treatments are already available across the rest of the UK. Whilst we're pleased this provides new hope, we recognise these drug cannot be used for everyone with the condition, and must ensure that no stone is left unturned in the hunt for new treatments. Full article here: https://bit.ly/3UROTeN 🔗

📣 Big News! We’re thrilled to announce that we’ve been named a Best Company at the Best Companies to work for awards, and secured multiple awards recognising our commitment to creating a fantastic workplace! 🎉 🏆 1st Place - Best Regional Company to Work For (Mid-Sized, London) 🏆 3rd Place - Top 25 Charities to Work For (Sector Award: National) 🏆 13th Place - Top 100 Mid-Sized Companies to Work For (National) And that’s not all! We’ve retained our 3 Star Accreditation, for a world-class level of workplace engagement 🌟 Being ranked as one of the top 5 charity employers in the UK is such an incredible honour. It highlights the importance that we place in our employees, knowing that a happy, engaged, and supported team is pivotal to our success, helping us achieve our mission: to beat blood cancer.

“I joined Walk of Light Birmingham to raise money for Blood Cancer UK and to shine a light on everyone with blood cancer. It was empowering for family, friends, and the community to come together and talk about its importance.” ✨ Nadine found out she had Hodgkin lymphoma, a type of blood cancer, in January 2024. It took a couple of months back-and-forth between the GP, urgent care, and A&E before getting a diagnosis. After treatment this summer, she’s now in remission! 🌟 “I’d recommend Walk of Light to everyone! It’s a great event for all ages, with shorter routes if you’re going through treatment or need to take it easier. There’s a real feel good atmosphere, especially at the finish line!” 🏮 💫 Sign up to join us at Walk of Light Birmingham on 29th March 2025, and walk 2.5km or 5km. Share this post and help us raise awareness. Together, we can be the generation to beat blood cancer. https://bit.ly/3Z4fUyk

Dr Rubina Ahmed, our Director of Research, Policy, and Services talks about the injustices of rare blood cancers, the lack of research investment, and how people can face limited treatment options 👇 https://lnkd.in/edz_SisJ

It's never too early to start planning Christmas! 🦌 🎄 Join us for an unforgettable evening at St Paul's Cathedral for Blood Cancer UK's Carol Concert. Taking place on Tuesday 17th December at 6.45pm, this enchanting event promises an evening of festive cheer and world-class music. Every ticket purchased supports our work for new, kinder treatments and life-saving research. Get yours now! ✨ https://bit.ly/48BlZoN 🔗

Exciting news – yesterday Minister Stephen Kinnock outlined the UK government's commitment to a National Cancer Plan. Blood cancer is the 5th most common cancer but as Clive Jones MP said during the debate, historically there's been a lack of strategic direction in blood cancer policy. Now is the time to address this and to create a brighter future for people with blood cancer, as outlined in our UK Blood Cancer Action Plan. Thank you to Clive Jones for raising this debate, and Max Wilkinson MP for sharing your experience of being affected by blood cancer.

To improve the lives of those with a type of blood cancer called follicular lymphoma, we’ve teamed up with the Follicular Lymphoma Foundation to support a world-class trial taking place at The Christie in Manchester 💊 This project which forms a sub-set of an ongoing clinical trial will give us a better understanding of how the drug, rituximab, could improve outcomes for people with the disease. Many people with this type of blood cancer can be treated but currently follicular lymphoma cannot be cured and will eventually come back. 👩🔬 In this trial, Dr Kim Linton and her team are identifying people who’ve not previously received treatment for their disease from around 65 NHS locations across the UK. They plan to closely monitor them for five years, looking at what order treatments are given to people, and to who, and how they respond. 🤝 Funding this trial in partnership with the Follicular Lymphoma Foundation is crucial for understanding and improving the delivery of treatments to people with follicular lymphoma. It will help us avoid giving people unnecessary toxic therapies, something that people with this blood cancer desperately need. Thank you to our community for helping us fund this research. More here: https://bit.ly/3Uueiel

Some types of blood cancer can be more common in certain ethnic groups. However not many people from ethnic minorities access blood cancer clinical trials. We want to change this and need your help. Are you from a Black or Pakistani background and have been affected by blood cancer? We need your help to make trials and research more accessible for your community. You'll be invited to participate in an interview or workshop to share your insights and experiences of blood cancer. It will take about 1-2 hours and you will be paid for your time. We are looking for people who: 🔴 Are from a Black or Pakistani background 🔴 Have a lived experience of blood cancer 🔴 You will be based in or work in London. If you're not based in London but received blood cancer treatment there, we'd love to hear from you. 🔴 Are over the age of 18 https://lnkd.in/eCF-Fa2S

Metric
Company Name	Blood Cancer UK	Childhood Eye Cancer Trust
Symbol
MSH ID	UK:ORG:BLOODCANCER	UK:ORG:CHECT
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Non-profit healthcare organization	Non-profit organization
Country	GB	GB
Stage
Employee Count
Website	bloodcancer.org.uk	chect.org.uk
LinkedIn	bloodcanceruk	childhood-eye-cancer-trust
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		216
Web Traffic Growth		0.79
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ORG

UK:ORG:BLOODCANCER

Blood Cancer UK

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue